Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The architectural arrangement of the neoplastic cells and their cytologic identification form the histologic basis of the Rappaport classification of non-Hodgkin's lymphomas clinical studies have shown the favorable prognosis of the nodular lymphomas while the diffuse lymphomas irrespective of cell type have a poor prognosis. Several recent studies have shown that pathologists can identify the nodular and diffuse patterns with a high degree of reproducibility. The cytologic subclassification has, however, not achieved a similar high degree of reproducibility. The Southwest Oncology Group study has shown the most reproducible subgroups to be the nodular poorly differentiated lymphocytic malignant lymphoma (ML) and the diffuse histiocytic ML. The clinical significance of the Rappaport classification when applied to childhood lymphomas is not as clear as in adult lymphomas. In view of the recent description of a new clinicopathologic entity primarily in children and adolescents (ie, lymphoblastic ML), IT IS APPARENT THAT THE CHILDHOOD LYMPHOMAS Will have to be examined more critically in order to determine the clinical significance of this classification. Although some have proposed new classifications of these lymphomas based upon immunologic identification of cell origin, none have been shown to be of clinical significance. Based on recent immunologic and clinical studies, a modified classification of the non-Hodgkin's lymphoma is proposed which does not alter its clinical usefulness.
 ...
PMID:Rappaport classification of non-Hodgkin's lymphoma: histologic features and clinical significance. 33 57

Five cases are reported where under curative aspects the splenic region was irradiated during radiation therapy of lymphogranulomatosis. In the course of this treatment, a radiation load amounting to 3000 up to 4200 R focal dose occurred to the upper pole of the left kidney. A LESION OF THE LEft kidney was diagnosed not earlier than nine or twelve months afterwards in three of the patients. Two patients could be followed up as yet only four or five months. As for verification of the circumscribed radiogenic nephritis, renal scintigraphy proved the best technique to provide information. Short-term check-up examinations are necessary for the purposes of early recognition and efficient therapy of this complication, the prognosis of lymphogranulomatosis being on the whole relatively good.
 ...
PMID:[Radiogenic nephritis in relation to splenectomy and irradiation of the spleen bed]. 127 76

Hype or hope? We have heard these words characterize recent reports on this country's so-called "war against cancer." For the eight million people like me who have had cancer, and for the millions that are being diagnosed this year, nothing happens soon enough. But, I am concerned about the message this type of reporting sends to people and the phones that then ring off the hook at my office from people who are desperately looking for a "cure for cancer." How are we going to translate this science into applications for people? How are people going to get access to it? We don't have a healthcare system that wants to pay for clinical research, which is what we're talking about here. This is a serious problem. And this problem is not new to us. My name is Ellen Stovall and I am one of this country's more than eight million cancer survivors. On December 23, 1971, President Richard Nixon signed into law the National Cancer Act. That day also marked something very personal for me. That was the day I began treatment for Hodgkin's disease. I remember going home that night rocking to sleep my two-month-old baby boy, Jonathan. He's now 26. And I remember my dear father calling me to tell me that he had seen the President on television that night, and that the President had declared a war on cancer for me. Today, that seven-year promise goes unfulfilled. Nearly 27 years later, we are still waiting. We have grown tired of waiting. We have been silent too long. We must begin to say, "NO MORE." On September 26, 1998, cancer survivors, their families, friends, caregivers, and co-workers-everyone whose life has been touched by cancer-will rally on The Mall in Washington, D.C. and in communities across the country as part of a national grassroots campaign to make cancer our nation's #1 research and healthcare priority. I invite you to join us in this campaign, called THE MARCH.Coming Together To Conquer Cancertrade mark.
 ...
PMID:THE MARCH: Coming Together to Conquer Cancertrade mark. 1038 97

FREQUENT IN THE CASE OF CANCER: According to a European multicentre study on 15 000 cancer patients, the percentage of anaemia exceeded 66% during the development of solid tumours and 72% during development of malignant tumours. The lowest levels of haemoglobin were correlated with the lowest performance status, however no treatment had been prescribed for anaemia in the majority of patients. MULTIPLE MYELOMAS AND LYMPHOMAS: The frequency of anaemia appeared just as high during these malignant affections and the correlation between haemoglobin levels and performance status was just as clear. Likewise, around one half of the anaemic patients had not been treated in an adapted or efficient manner. SIGNIFICANCE OF ANEMIA DURING LYMPHOMAS: It appeared that the anaemia of Hodgkin's disease, related to the inflammation, was correlated with shorter survival, whereas the anaemia of non-hodgkin lymphoma, related to medullar infiltration, generally affected the complete rate of response.
 ...
PMID:[Epidemiological data on anaemia during malignant affections]. 1453 1

Classical Hodgkin lymphoma (cHL) is a particular kind of malignant tumour that originates from the B cells. The malignant phenotype of cHL is, at least in part, maintained by epigenetic aberrations, which primarily consist of abnormal histone methylation and acetylation. Progress has been made in clinical trials concerning the histone deacetylases inhibitors (HDACis) in cHL. Also, some demethylation regimens could serve the purpose of preventing and treating tumours. Programmed death-ligand receptor 1 (PD-L1, CD274) inhibitors or apoptosis receptor 1 (PD-1, CD279) inhibitors are used in treating patients with relapsed cHL in recent years. Academic researches indicated that PD-1/PD-L1 inhibitors, including nivolumab and pembrolizumab, demonstrate remarkable activity in relapsed cHL. In addition, in recent years, a close association between epigenetic aberrations and immune escape has been explored in cHL. DNA methyltransferase (DNMT) inhibitors, HDACis, and immune checkpoint blockade exhibit synergistic effects. Thus, this review aims to provide an overview on the epigenetic abnormalities of cHL and its effect on immune escape, in order to explore the optimal combination approach to treat the disease. SIGNIFICANCE OF THE STUDY: Cancer Statistics 2018 reported that more than 8000 new cases of Hodgkin lymphoma were diagnosed. In recent years, PD-1/PD-L1 inhibitors for cHL have been utilized, and the therapeutic strategies of HDACis combined with PD-1/PD-L1 inhibitors have been raised. It is critical for improving the efficacy and decreasing the toxicity in treating the patients with cHL.
 ...
PMID:Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. 3170 94